TY - JOUR
T1 - Propensity Score-Based Analysis of Percutaneous Closure Versus Medical Therapy in Patients with Cryptogenic Stroke and Patent Foramen Ovale
T2 - The IPSYS Registry (Italian Project on Stroke in Young Adults)
AU - Pezzini, A.
AU - Grassi, M.
AU - Lodigiani, Corrado
AU - Patella, R.
AU - Gandolfo, Carlo
AU - Zini, Andrea
AU - Delodovici, M. Luisa
AU - Paciaroni, Maurizio
AU - Del Sette, Massimo
AU - Toriello, Antonella
AU - Musolino, R.
AU - Calabrò, Rocco Salvatore
AU - Bovi, P.
AU - Adami, Alessandro
AU - Silvestrelli, Giorgio
AU - Sessa, Maria
AU - Cavallini, Anna Maria
AU - Marcheselli, Simona
AU - Marco Bonifati, Domenico
AU - Checcarelli, N.
AU - Tancredi, L.
AU - Chiti, Alberto
AU - Del Zotto, Elisabetta
AU - Tomelleri, G.
AU - Spalloni, A.
AU - Giorli, Elisa
AU - Costa, Paolo
AU - Giacalone, Giacomo
AU - Ferrazzi, Paola
AU - Poli, Loris
AU - Morotti, Andrea
AU - Piras, Valeria
AU - Rasura, Maurizia
AU - Simone, Anna Maria
AU - Gamba, Massimo
AU - Cerrato, Paolo
AU - Zedde, M.
AU - Micieli, Giuseppe
AU - Melis, Maurizio
AU - Massucco, Davide
AU - Guido, Davide
AU - De Giuli, Valeria
AU - Bonaiti, Silvia
AU - D'Amore, Cataldo
AU - La Starza, S.
AU - Iacoviello, Licia
AU - Padovani, A.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background-We sought to compare the benefit of percutaneous closure to that of medical therapy alone for the secondary prevention of embolism in patients with patent foramen ovale (PFO) and otherwise unexplained ischemic stroke, in a propensity scored study. Methods and Results-Between 2000 and 2012, we selected consecutive first-ever ischemic stroke patients aged 18 to 45 years with PFO and no other cause of brain ischemia, as part of the IPSYS registry (Italian Project on Stroke in Young Adults), who underwent either percutaneous PFO closure or medical therapy for comparative analysis. Primary end point was a composite of ischemic stroke, transient ischemic attack, or peripheral embolism. Secondary end point was brain ischemia. Five hundred and twenty-one patients qualified for the analysis. The primary end point occurred in 15 patients treated with percutaneous PFO closure (7.3%) versus 33 patients medically treated (10.5%; hazard ratio, 0.72; 95% confidence interval, 0.39-1.32; P=0.285). The rates of the secondary end point brain ischemia were also similar in the 2 treatment groups (6.3% in the PFO closure group versus 10.2% in the medically treated group; hazard ratio, 0.64; 95% confidence interval, 0.33-1.21; P=0.168). Closure provided a benefit in patients aged 18 to 36 years (hazard ratio, 0.19; 95% confidence interval, 0.04-0.81; P=0.026) and in those with a substantial right-to-left shunt size (hazard ratio, 0.19; 95% confidence interval, 0.05-0.68; P=0.011). Conclusions-PFO closure seems as effective as medical therapy for secondary prevention of cryptogenic ischemic stroke. Whether device treatment might be more effective in selected cases, such as in patients younger than 37 years and in those with a substantial right-to-left shunt size, deserves further investigation.
AB - Background-We sought to compare the benefit of percutaneous closure to that of medical therapy alone for the secondary prevention of embolism in patients with patent foramen ovale (PFO) and otherwise unexplained ischemic stroke, in a propensity scored study. Methods and Results-Between 2000 and 2012, we selected consecutive first-ever ischemic stroke patients aged 18 to 45 years with PFO and no other cause of brain ischemia, as part of the IPSYS registry (Italian Project on Stroke in Young Adults), who underwent either percutaneous PFO closure or medical therapy for comparative analysis. Primary end point was a composite of ischemic stroke, transient ischemic attack, or peripheral embolism. Secondary end point was brain ischemia. Five hundred and twenty-one patients qualified for the analysis. The primary end point occurred in 15 patients treated with percutaneous PFO closure (7.3%) versus 33 patients medically treated (10.5%; hazard ratio, 0.72; 95% confidence interval, 0.39-1.32; P=0.285). The rates of the secondary end point brain ischemia were also similar in the 2 treatment groups (6.3% in the PFO closure group versus 10.2% in the medically treated group; hazard ratio, 0.64; 95% confidence interval, 0.33-1.21; P=0.168). Closure provided a benefit in patients aged 18 to 36 years (hazard ratio, 0.19; 95% confidence interval, 0.04-0.81; P=0.026) and in those with a substantial right-to-left shunt size (hazard ratio, 0.19; 95% confidence interval, 0.05-0.68; P=0.011). Conclusions-PFO closure seems as effective as medical therapy for secondary prevention of cryptogenic ischemic stroke. Whether device treatment might be more effective in selected cases, such as in patients younger than 37 years and in those with a substantial right-to-left shunt size, deserves further investigation.
KW - atrial septum
KW - follow-up studies
KW - patent foramen ovale
KW - secondary prevention
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=84988683862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988683862&partnerID=8YFLogxK
U2 - 10.1161/CIRCINTERVENTIONS.115.003470
DO - 10.1161/CIRCINTERVENTIONS.115.003470
M3 - Article
SN - 1941-7640
VL - 9
JO - Circulation: Cardiovascular Interventions
JF - Circulation: Cardiovascular Interventions
IS - 9
M1 - e003470
ER -